**Name of Journal: *World Journal of Hepatology***

**EPS Manuscript NO: 23052**

**Manuscript Type: Review**

**Sofosbuvir treatment and hepatitis C virus infection**

Nakamura M *et al.* Sofosbuvir and HCV

**Masato Nakamura, Tatsuo Kanda, Yuki Haga, Reina Sasaki, Shuang Wu, Shingo Nakamoto, Shin Yasui, Makoto Arai, Fumio Imazeki, Osamu Yokosuka**

**Masato Nakamura, Tatsuo Kanda, Yuki Haga, Reina Sasaki, Shuang Wu, Shingo Nakamoto, Shin Yasui, Makoto Arai, Fumio Imazeki, Osamu Yokosuka,** Department of Gastroenterology and Nephrology, Chiba University, Graduate School of Medicine, Chiba 260-8670, Japan

**Shingo Nakamoto,** Department of Molecular Virology, Chiba University, Graduate School of Medicine, Chiba 260-8677, Japan

**Fumio Imazeki,** Safety and Health Organization, Chiba University, Chiba 263-8522, Japan

**Author contributions:** All authors equally contributed to this paper with conception and design of the study, literature review and analysis, drafting and critical revision and editing, and final approval of the final version.

**Conflict-of-interest statement:** Kanda T reports receiving lecture fees from Chugai Pharmaceutical, MSD, Tanabe-Mitsubishi, Ajinomoto, Bristol-Myers Squibb, Daiichi-Sankyo, Janssen Pharmaceutical and GlaxoSmithKline; Yokosuka O reports receiving grant support from Chugai Pharmaceutical, Bayer, MSD, Daiichi-Sankyo, Tanabe-Mitsubishi, Bristol-Myers Squibb, Gilead Sciences and Taiho Pharmaceutical. None of the other authors have any conflicts of interest or financial support to declare.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Correspondence to: Tatsuo Kanda, MD, PhD, Associate Professor,** Department of Gastroenterology and Nephrology, Chiba University, Graduate School of Medicine, 1-8-1 Inohana, Chuo-ku, Chiba 260-8677, Japan. kandat-cib@umin.ac.jp

**Telephone:** +81-43-2262086

**Fax:** +81-43-2262088

**Received:** October 15, 2015

**Peer-review started:** October 16, 2015

**First decision:** November 24, 2015

**Revised:** November 27, 2015

**Accepted:** January 5, 2016

**Article in press:**

**Published online:**

**Abstract**

Hepatitis C virus (HCV) infection is a serious problem worldwide. The use of interferon-based therapy has made HCV eradication challenging. The recent appearance of direct-acting antiviral agents (DAAs) has changed HCV therapy. Combining the use of DAAs with peginterferon and ribavirin has improved treatment efficacy. Furthermore, the combination of different orally administered DAAs has enabled interferon-free therapy with much higher efficacy and safety. In particular, sofosbuvir, a nucleotide-based NS5B inhibitor, prevents HCV RNA synthesis by acting as a “chain terminator”. Treatment with sofosbuvir has attained an extremely high rate of sustained virologic response. The current review summarizes the efficacy and safety of sofosbuvir therapy.

**Key words:** Hepatitis C virus; Interferon; Interferon-free; Genotype; Sofosbuvir

**© The Author(s) 2016.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** Sofosbuvir, a nucleotide-based NS5B inhibitor, is an effective treatment against pangenotypic strains of hepatitis C virus (HCV). Sofosbuvir-containing regimens have attained extremely high rates of sustained virologic response. Because regimens including sofosbuvir result in fewer adverse events than interferon-based regimens, sofosbuvir has taken a central role in HCV treatment.

Nakamura M, Kanda T, Haga Y, Sasaki R, Wu S, Nakamoto S, Yasui S, Arai M, Imazeki F, Yokosuka O. Sofosbuvir treatment and hepatitis C virus infection. *World J Hepatol* 2016; In press

**INTRODUCTION**

Hepatitis C virus (HCV) infection is a global public health problem. Approximately 130 to 170 million people experience chronic HCV infection, which has a global prevalence of 2%-3%[1,2]. In 2002, worldwide, 27% of 783000 deaths from cirrhosis and 25% of 619000 deaths from hepatocellular carcinoma (HCC) were attributed to HCV infection[3].

The use of interferon-based therapy has made HCV eradication challenging, especially for patients infected with HCV genotype 1. Treatment with peginterferon plus ribavirin induces only about 50% of patients infected with HCV genotype 1 at high viral loads to achieve sustained virologic response (SVR)[4], while about 80% of patients infected with HCV genotypes 2 and 3 achieve SVR[5].

The appearance of direct-acting antiviral agents (DAAs), which specifically target HCV proteins, has provided insights into the current situation. The use of protease inhibitors, such as telaprevir, boceprevir, simeprevir, faldaprevir and vaniprevir, in combination with peginterferon and ribavirin has improved treatment efficacy in treatment-naïve patients (70% to 80% achieve SVR) and in patients infected with HCV genotype 1 who have relapsed post-treatment[6-10]. However, SVR rates in patients who exhibited no responses to previous treatments remain low[11-12]. Furthermore, patients who are ineligible for or intolerant to treatment with peginterferon plus ribavirin are contra-indicated from receiving the above treatment.

The use of combinations of different orally administered DAAs has enabled the realization of interferon-free therapy. DAA-based therapies generally have higher treatment efficacy and lower risk for adverse effects compared to regimens using interferon. In particular, sofosbuvir, a pyrimidine nucleoside analog inhibitor of HCV pangenotype NS5B polymerase, has produced extremely high rates of SVR when used in combination with other DAAs. In the current review, we discuss the use of treatment regimens that include sofosbuvir to combat HCV.

**STRUCTURE OF HCV GENOME AND DAAS**

HCV is an enveloped, positive-stranded RNA virus. Its genome spans 9600 nucleotides in length and contains a 5' non-translated region (5' NTR), a single open reading frame (ORF) and a 3' NTR. A single polyprotein is translated from HCV genome and is then cleaved into structural (core, E1, E2 and p7) and non-structural (NS2, NS3, NS4A, NS4B, NS5A and NS5B) proteins[4]. The serine protease NS3 plays a key role in processing the HCV polyprotein. The phosphoprotein NS5A and RNA-dependent RNA polymerase NS5B are essential to the replication of HCV RNA. DAAs against HCV target these proteins and strongly inhibit HCV replication.

The first-generation NS3/4A protease inhibitors telaprevir and boceprevir are typically used in combination with peginterferon and ribavirin. This triple regimen has improved SVR rates in HCV genotype 1-infected patients[6,7] but often produces serious adverse events[13]. The second-generation NS3/4A protease inhibitors simeprevir, faldaprevir and vaniprevir have further improved treatment efficacy while resulting in fewer adverse effects[8-10].

In Japan, daclatasvir, a first-in-class NS5A inhibitor, enabled effective interferon-free therapy for the first time. Interferon-free dual oral therapy with DCV and asunaprevir, a NS3/4A protease inhibitor, led to high SVR rates (87.4% in interferon-ineligible or -intolerant patients, 80.5% in non-responders, 89.1% in treatment-naïve patients, and 95.5% in relapsers)[14-15]. However, the evolution of drug-resistant HCV variants has created new problems. For example, Y93H variants of the NS5A protein have markedly decreased SVR rates to as low as 43.3%[14].

***Sofosbuvir***

Sofosbuvir (formerly known as GS-7977; Gilead Sciences, Foster City, CA, United States) is a nucleotide NS5B inhibitor[16]. Sofosbuvir is converted into a pharmacologically active form (GS-461203) within hepatocytes[17]. GS-461203 inhibits RNA-dependent RNA polymerase activity by competing with uridine and prevents HCV RNA synthesis by acting as “chain terminator”. Because the catalytic site of the NS5B protein is highly conserved, sofosbuvir is believed to have pangenotypic activity[18].

Another favorable characteristic of sofosbuvir is its high genetic barrier. In an HCV replicon study, a S282T substitution in NS5B was reported to impart drug resistance[19]. However, in clinical trials, this NS5B variant was detected in only one patient after treatment with sofosbuvir monotherapy[16,20-22]. Foster *et al*[23] reported that sofosbuvir treatment led to the emergence of drug-resistant variants in 9/78 (12%) of patients. An L159F variant was present both at baseline and at the time of virologic failure in 1 patient and at the time of virologic failure in 7 additional patients. The V321A variant emerged at the time of virologic failure in 2 patients.

Sofosbuvir also possess a noteworthy safety profile and high tolerability. In phase 3 trials of sofosbuvir, the frequency of serious adverse events (SAEs) ranged from 1% to 8% and the rate of treatment discontinuation because of adverse events range from 0 to 4.4%[24,25].

**CLINICAL EFFICACY OF TREATMENT REGIMEN CONTAINING SOFOSBUVIR**

More than 3000 patients have been assessed in clinical studies of treatment regimens containing sofosbuvir. Below, we describe the efficacy of a sofosbuvir-containing regimen.

***HCV genotype 1-specific virologic response of sofosbuvir***

The results from phase 3 clinical trials evaluating the use of treatment regimens containing sofosbuvir against HCV genotype 1 are shown in Table 1. The NEUTRINO study was the first phase 3 trial to evaluate sofosbuvir-containing therapy[26]. In this single-group, open-label study, 291 treatment-naïve patients infected with HCV genotype 1 were treated with sofosbuvir plus peginterferon and ribavirin for 12 wk. The patients attained a high rate of SVR at 12 wk after completion of therapy (SVR12) (89%) and had a low rate of treatment discontinuation (2%) compared with historical controls. This study demonstrated the efficacy and safety of combining sofosbuvir with peginterferon and ribavirin; however, patients contraindicated for peginterferon or ribavirin were excluded.

Based on high rates of SVR in phase 2 studies, phase 3 ION studies were conducted to assess a fixed-dose combination of sofosbuvir and ledipasvir[27-30]. In the ION-1 trial, 865 treatment-naïve patients infected with HCV genotype 1 were randomly divided into four groups and received either 12 wk or 24 wk of sofosbuvir and ledipasvir with or without ribavirin. High SVR12 rates were attained in all groups (range: 97% - 99%), and no patients in either 12-wk group discontinued therapy because of adverse events[28].

The ION-2 trial was conducted to evaluate the combination of sofosbuvir and ledipasvir with or without ribavirin in treatment-experienced patients. In this trial, 440 patients were divided into groups and treated with either 12 wk or 24 wk of sofosbuvir and ledipasvir with or without RBV. As in the ION-1 trial, high SVR12 rates were attained in all treatment groups (range: 94% - 99%). No cases of treatment discontinuation owing to adverse events were reported[29].

The ION-3 trial was conducted to evaluate the feasibility of shorter duration therapy in previously untreated patients without cirrhosis. The noninferiority of an 8-wk regimen was demonstrated by the similar SVR12 rates in all groups (range: 93%-95%)[30]. The results from the ION-3 trial also indicated that an 8-wk regimen of sofosbuvir plus ledipasvir is not generally equal to 12 wk of treatment; however, international guidelines recommend that an HCV RNA threshold of 6 million IU/mL is maintained.

Among Asian countries, Mizokami *et al*[25] reported a phase 3 study conducted to evaluate Japanese patients. In this study, 166 treatment-naïve and 175 treatment-experienced patients received 12 wk of sofosbuvir and ledipasvir with or without ribavirin. High SVR12 rates (range: 96%-100%) were also attained in this study. This is noteworthy, as Japanese patients tend to be older, have more advanced fibrosis and are more frequently treated with previous therapy than patients in other countries. In the above studies, the inclusion of ribavirin in the treatment regimens produced no additional benefit. Furthermore, adverse events were more common in groups treated with ribavirin than in those without ribavirin.

The SOLAR-1 and SOLAR-2 studies showed the usefulness of sofosbuvir plus ledipasvir for decompensated cirrhosis[31,32]. In patients with cirrhosis and moderate or severe hepatic impairment who had not undergone liver transplantation, 86%-89% SVR12 rates were achieved[31]. In patients who had undergone liver transplantation, 96%-98%, 85%-88%, and 60%-75% SVR12 rates were achieved in patients without cirrhosis or with well-compensated cirrhosis, patients with moderate hepatic impairment, and patients with severe hepatic impairment, respectively[31]. All 6 patients with fibrosing cholestatic hepatitis achieved SVR12. Response rates in the 12- and 24-week treatment groups were similar[31]. The use of sofosbuvir plus simeprevir for 12 and 8 weeks in HCV genotype 1-infected patients without cirrhosis resulted in 83% and 97% SVR12 rates, respectively[33]. Likewise, the use of sofosbuvir plus simeprevir for 12 weeks resulted in an 83% SVR12 rate in HCV genotype 1-infected patients with cirrhosis[34].

***HCV genotype 2-specific virologic response of sofosbuvir***

The results from phase 3 clinical trials evaluating the use of treatments containing sofosbuvir against HCV genotype 2-infected patients are shown in Table 2.Three phase 3 trials have evaluated previously untreated patients (the FISSION, POSITRON and VALENCE studies)[23, 29-31]. In the FISSION study, 12 wk of sofosbuvir plus ribavirin treatment and 24 wk of peginterferon α-2a plus ribavirin treatment produced comparable results in treatment-naïve patients. The SVR12 rate was 97% in a group of 70 patients who received sofosbuvir plus ribavirin and 78% in a group of 67 patients who received Peg-IFNα2a plus ribavirin. The noninferiority of the sofosbuvir plus ribavirin regimen relative to interferon-based therapy was shown. Furthermore, adverse events were less frequent with the sofosbuvir plus ribavirin regimen[26,35].

In the POSITRON study, 109 patients for whom treatment with Peg-IFN was not an option received 12 wk of sofosbuvir plus ribavirin, and 78% of these patients achieved SVR12[36]. These results were confirmed by the VALENCE study, in which 97% of 32 treatment-naïve patients achieved SVR12[37].

In addition, the FUSION study[36] and the other arm of the VALENCE study evaluated the use of a sofosbuvir plus ribavirin regimen in treatment-experienced patients. In the FUSION study, 103 patients received sofosbuvir plus ribavirin for 12 wk, and 98 patients received the treatment for 16 wk. The rates of SVR12 were 86% and 94% in the 12-wk and 16-wk groups, respectively[36].

Omata *et al*[38] reported the efficacy and safety of a 12-wk sofosbuvir plus ribavirin treatment in Japanese patients. The rates of SVR12 were 98% and 95% in treatment-naïve and previously treated patients, respectively. According to these trials, the use of sofosbuvir plus ribavirin has become a standard of care for the treatment of HCV genotype 2-infected patients.

***HCV genotype 3-specific virologic response of sofosbuvir***

HCV genotype 3 has become the most difficult genotype to cure in the era of interferon-free therapy. Although sofosbuvir is considered to have pangenotypic inhibitory activities, its treatment efficacy against HCV genotype 3 is lower than against the other genotypes. The results from phase 3 clinical trials evaluating treatments containing sofosbuvir to combat HCV genotype 3 are shown in Table 3.

In the FISSION study, SVR12 occurred in 56% of patients who received 12 wk of sofosbuvir plus ribavirin and in 63% of patients who received 24 wk of peginterferon plus ribavirin. These results were poor, as 97% of patients infected with HCV genotype 2 achieved SVR12 following treatment with sofosbuvir plus ribavirin in the same study[26,35].

The results of the POSITRON study were similar to those of the FISSION study. In the FISSION study, 61% patients infected with HCV genotype 3 achieved SVR12 compared to 93% of patients infected with HCV genotype 2. The rate of SVR12 in patients with cirrhosis was especially low in the HCV genotype 3 group (21%)[36].

Although the above results are somewhat disappointing, extending the duration of treatment might improve sofosbuvir’s efficacy against HCV genotype 3. In the FUSION study, 16 wk of sofosbuvir plus ribavirin therapy resulted in higher SVR12 rates than 12 wk therapy (37% *vs* 63% in patients without cirrhosis; 19% *vs* 61% in patients with cirrhosis)[36].

In addition, the VALENCE study was conducted to assess the efficacy of 24 wk of sofosbuvir plus ribavirin treatment in 250 HCV genotype 3-infected patients[37]. The rates of SVR12 were 95% and 92% in treatment-naïve patients with and without cirrhosis, respectively, and 87% and 62% in previously treated patients with and without cirrhosis. A longer treatment duration was not associated with a higher frequency of adverse events or treatment discontinuation. However, further studies will be necessary to improve treatment efficacy in previously treated patients with cirrhosis.

Foster *et al*[23] reported a 93% SVR12 rate following 12 wk of treatment with peginterferon, sofosbuvir and ribavirin *vs* an 84% SVR12 rate following 24 wk of treatment with sofosbuvir plus ribavirin *vs* an 88% SVR12 rate following 12 wk of treatment with peginterferon, sofosbuvir and ribavirin in cirrhotic patients. Treatment with daclatasvir plus sofosbuvir for 12 wk led to a 96% SVR12 rate in HCV genotype 3-infected patients without cirrhosis[39].

***Other HCV genotypes-specific virologic response of sofosbuvir***

In the NEUTRINO study, 35 patients infected with HCV genotypes 4 through 6 were treated with sofosbuvir, ribavirin and peginterferon for 12 wk. The rates of SVR12 were 96% and 100% in patients infected with HCV genotypes 4 and 5-6, respectively[26]. A treatment regimen that contains sofosbuvir might therefore be efficient against these genotypes.

The use of a ribavirin- and interferon-free regimen of ledipasvir/sofosbuvir for 12 weeks resulted in an SVR4 rate of 93% in genotype 4 and genotype 5 HCV-infected treatment-naïve and treatment-experienced patients with or without cirrhosis[40].

***HIV Co-infection***

The PHOTON-1 and -2 studies were conducted to evaluate the use of sofosbuvir plus ribavirin therapy to combat HCV-HIV co-infection[41,42]. The results of these trials are summarized in Table 4.

In the PHOTON-1 study, in patients infected with HCV genotype 1, 12 weeks of sofosbuvir plus ribavirin led to a 78% SVR12 rate. Extending treatment to 24 wk tended to result in higher rates of SVR (85%)[41].

The use of a longer treatment duration also appeared to be effective in treatment-naïve patients infected with HCV genotype 3. Similar to the results from the study against HCV genotype 3 infection alone, 12 weeks of sofosbuvir plus ribavirin therapy attained low rates of SVR12 compared with other genotypes in the PHOTON-1 study (67%)[32]. Extending treatment from 12 wk to 24 wk improved the rate of SVR12 in the PHOTON-2 study (91%)[42]. Among patients infected with other HCV genotypes, high rates of SVR12 (83%-92%) were attained after 12 wk of sofosbuvir plus ribavirin treatment in treatment-naïve patients and 24 wk of the above treatment in previously treated patients[41,42].

The ALLY-2 study examined the use of daclatasvir plus sofosbuvir in patients co-infected with HIV and HCV genotype 1. The results showed that SVR rates were 96.4% following 12 weeks of treatment and 75.6% following 8 weeks of treatment in treatment-naive patients. The SVR12 rate was 97.7% in treatment-experienced patients following 12 wk of treatment with the above regimen[43].

The ION-4 study evaluated the use of ledipasvir plus sofosbuvir for 12 weeks in HIV co-infected patients. The SVR12 rates were 96% in HCV genotype 1a-infected patients, 96% in HCV genotype 1b-infected patients, and 100% in HCV genotype 4-infected patients[44].

**CONCLUSION**

Sofosbuvir, a first-in-class NS5B inhibitor, has rapidly become the standard of care for the treatment of numerous HCV genotypes. However, its efficacy against HCV genotype 3, especially in patients with cirrhosis, has not been satisfactory. The optimal duration of treatment and use of novel combinations with other DAAs should be examined in the future.

Patients with severe renal impairment [estimated glomerular filtration rate (eGFR) < 30 mL/min/1.73 m2] and on hemodialysis are contraindicated for sofosbuvir-containing regimens. This limitation of sofosbuvir should be recognized. Nevertheless, sofosbuvir is an important drug that possesses high efficacy and safety. Sofosbuvir-containing therapy has become a standard of care for the majority of patients with HCV infections.

**REFERENCES**

1 **Gower E**, Estes CC, Hindman S, Razavi-Shearer K, Razavi H. Global epidemiology and genotype distribution of the hepatitis C virus infection. *J Hepatol* 2014; **61** (Suppl): 45–57 [PMID: 25086286 DOI: 10.1016/j.jhep.2014.07.027]

2 **Lavanchy D**. The global burden of hepatitis C. *Liver Int* 2009; **29** Suppl 1: 74-81 [PMID: 19207969 DOI: 10.1111/j.1478-3231.2008.01934.x]

3 **Perz JF**, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. *J Hepatol* 2006; **45**: 529-538 [PMID: 16879891 DOI: 10.1016/j.jhep.2006.05.013]

4 **Kanda T**, Imazeki F, Yokosuka O. New antiviral therapies for chronic hepatitis C. *Hepatol Int* 2010; **4**: 548-561 [PMID: 21063477 DOI: 10.1007/s12072-010-9193-3]

5 **Lagging M**, Rembeck K, Rauning Buhl M, Christensen P, Dalgard O, Färkkilä M, Hellstrand K, Langeland N, Lindh M, Westin J, Norkrans G. Retreatment with peg-interferon and ribavirin in patients with chronic hepatitis C virus genotype 2 or 3 infection with prior relapse. *Scand J Gastroenterol* 2013; **48**: 839-847 [PMID: 23795661 DOI: 10.3109/00365521.2013.793389]

6 **Jacobson IM**, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, Marcellin P, Muir AJ, Ferenci P, Flisiak R, George J, Rizzetto M, Shouval D, Sola R, Terg RA, Yoshida EM, Adda N, Bengtsson L, Sankoh AJ, Kieffer TL, George S, Kauffman RS, Zeuzem S. Telaprevir for previously untreated chronic hepatitis C virus infection. *N Engl J Med* 2011; **364**: 2405-2416 [PMID: 21696307 DOI: 10.1056/NEJMoa1012912]

7 **Poordad F**, McCone J, Bacon BR, Bruno S, Manns MP, Sulkowski MS, Jacobson IM, Reddy KR, Goodman ZD, Boparai N, DiNubile MJ, Sniukiene V, Brass CA, Albrecht JK, Bronowicki JP. Boceprevir for untreated chronic HCV genotype 1 infection. *N Engl J Med* 2011; **364**: 1195-1206 [PMID: 21449783 DOI: 10.1056/NEJMoa1010494]

8 **Fried MW**, Buti M, Dore GJ, Flisiak R, Ferenci P, Jacobson I, Marcellin P, Manns M, Nikitin I, Poordad F, Sherman M, Zeuzem S, Scott J, Gilles L, Lenz O, Peeters M, Sekar V, De Smedt G, Beumont-Mauviel M. Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C: the randomized PILLAR study. *Hepatology* 2013; **58**: 1918-1929 [PMID: 23907700 DOI: 10.1002/hep.26641]

9 **Sulkowski MS**, Asselah T, Lalezari J, Ferenci P, Fainboim H, Leggett B, Bessone F, Mauss S, Heo J, Datsenko Y, Stern JO, Kukolj G, Scherer J, Nehmiz G, Steinmann GG, Böcher WO. Faldaprevir combined with pegylated interferon alfa-2a and ribavirin in treatment-naïve patients with chronic genotype 1 HCV: SILEN-C1 trial. *Hepatology* 2013; **57**: 2143-2154 [PMID: 23359516 DOI: 10.1002/hep.26276]

10 **Rodriguez-Torres M**, Stoehr A, Gane EJ, Serfaty L, Lawitz E, Zhou A, Bourque M, Bhanja S, Strizki J, Barnard RJ, Hwang PM, DiNubile MJ, Mobashery N. Combination of vaniprevir with peginterferon and ribavirin significantly increases the rate of SVR in treatment-experienced patients with chronic HCV genotype 1 infection and cirrhosis. *Clin Gastroenterol Hepatol* 2014; **12**: 1029-37.e5 [PMID: 24120953 DOI: 10.1016/j.cgh.2013.09.067]

11 **Zeuzem S**, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, Focaccia R, Younossi Z, Foster GR, Horban A, Ferenci P, Nevens F, Müllhaupt B, Pockros P, Terg R, Shouval D, van Hoek B, Weiland O, Van Heeswijk R, De Meyer S, Luo D, Boogaerts G, Polo R, Picchio G, Beumont M. Telaprevir for retreatment of HCV infection. *N Engl J Med* 2011; **364**: 2417-2428 [PMID: 21696308 DOI: 10.1056/NEJMoa1013086]

12 **Bacon BR**, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, Poordad F, Goodman ZD, Sings HL, Boparai N, Burroughs M, Brass CA, Albrecht JK, Esteban R. Boceprevir for previously treated chronic HCV genotype 1 infection. *N Engl J Med* 2011; **364**: 1207-1217 [PMID: 21449784 DOI: 10.1056/NEJMoa1009482]

13 **D’Ambrosio R,** Colombo M. Safety and direct antiviral agents in real life. *Dig  Liver Dis* 2013; **45**: S363–S366 [PMID: 24091117 DOI: 10.1016/j.dld.2013.07.012]

14 **Kumada H**, Suzuki Y, Ikeda K, Toyota J, Karino Y, Chayama K, Kawakami Y, Ido A, Yamamoto K, Takaguchi K, Izumi N, Koike K, Takehara T, Kawada N, Sata M, Miyagoshi H, Eley T, McPhee F, Damokosh A, Ishikawa H, Hughes E. Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection. *Hepatology* 2014; **59**: 2083-2091 [PMID: 24604476 DOI: 10.1002/hep.27113]

15 **Kumada H**, Suzuki F, Suzuki Y, Toyota J, Karino Y, Chayama K, Kawakami Y, Fujiyama S, Ito T, Itoh Y, Tamura E, Ueki T, Ishikawa H, Hu W, McPhee F, Linaberry M, Hughes E. Randomized comparison of daclatasvir + asunaprevir versus telaprevir + peginterferon/ribavirin in Japanese HCV patients. *J Gastroenterol Hepatol* 2015; Epub ahead of print [PMID: 26252875 DOI: 10.1111/jgh.13073]

16 **Gane EJ**, Stedman CA, Hyland RH, Ding X, Svarovskaia E, Symonds WT, Hindes RG, Berrey MM. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. *N Engl J Med* 2013; **368**: 34-44 [PMID: 23281974 DOI: 10.1056/NEJMoa1208953]

17 **Murakami E**, Tolstykh T, Bao H, Niu C, Steuer HM, Bao D, Chang W, Espiritu C, Bansal S, Lam AM, Otto MJ, Sofia MJ, Furman PA. Mechanism of activation of PSI-7851 and its diastereoisomer PSI-7977. *J Biol Chem* 2010; **285**: 34337-34347 [PMID: 20801890 DOI: 10.1074/jbc.M110.161802]

18 **Lam AM**, Espiritu C, Bansal S, Micolochick Steuer HM, Niu C, Zennou V, Keilman M, Zhu Y, Lan S, Otto MJ, Furman PA. Genotype and subtype profiling of PSI-7977 as a nucleotide inhibitor of hepatitis C virus. *Antimicrob Agents Chemother* 2012; **56**: 3359-3368 [PMID: 22430955 DOI: 10.1128/AAC.00054-12]

19 **Kowdley KV**, Hassanein T, Gane EJ. Sofosbuvir safety and tolerability in 741 patients treated for up to 24 weeks. *J Hepatol* 2013; **58**: s345

20 **Ludmerer SW**, Graham DJ, Boots E, Murray EM, Simcoe A, Markel EJ, Grobler JA, Flores OA, Olsen DB, Hazuda DJ, LaFemina RL. Replication fitness and NS5B drug sensitivity of diverse hepatitis C virus isolates characterized by using a transient replication assay. *Antimicrob Agents Chemother* 2005; **49**: 2059-2069 [PMID: 15855532]

21 **Svarovskaia E,** Dvory-Sobol H, Gontcharova V, Martin R, Hyland R, Symonds WT, Lalezari J, Miller MD, Mo H. No S282T mutation detected by deep sequencing in a large number of HCV patients who received GS-7977 with RBV and/or GS-0938: the QUANTUM study. *J Hepatol* 2013; **58**: S496

22 **Svarovskaia ES**, Dvory-Sobol H, Parkin N, Hebner C, Gontcharova V, Martin R, Ouyang W, Han B, Xu S, Ku K, Chiu S, Gane E, Jacobson IM, Nelson DR, Lawitz E, Wyles DL, Bekele N, Brainard D, Symonds WT, McHutchison JG, Miller MD, Mo H. Infrequent development of resistance in genotype 1-6 hepatitis C virus-infected subjects treated with sofosbuvir in phase 2 and 3 clinical trials. *Clin Infect Dis* 2014; **59**: 1666-1674 [PMID: 25266287 DOI: 10.1093/cid/ciu697]

23 **Foster GR**, Pianko S, Cooper C, Brown A, Forton D, Nahass RG, George J, Barnes E, Brainard DM, Massetto B, Lin M, McHutchison JG, Subramanian GM, Agarwal K. Sofosbuvir peginterferon/ribavirin for 12 weeks vs sofosbuvir ribavirin for 16 or 24 weeks in genotype 3 HCV infected patients and treatment-experienced cirrhotic patients with genotype 2 HCV: The boson study. *J Hepatol* 2015; **62**: S259-S262 [DOI: 10.1016/S0168-8278(15)30151-3]

24 **Liu X**, Wang Y, Zhang G, Li N, Zhu Q, Chang H, Han Q, Lv Y, Liu Z. Efficacy and safety of sofosbuvir-based therapy for the treatment of chronic hepatitis C in treatment-naïve and treatment-experienced patients. *Int J Antimicrob Agents* 2014; **44**: 145-151 [PMID: 25034873 DOI: 10.1016/j.ijantimicag.2014.04.018]

25 **Mizokami M**, Yokosuka O, Takehara T, Sakamoto N, Korenaga M, Mochizuki H, Nakane K, Enomoto H, Ikeda F, Yanase M, Toyoda H, Genda T, Umemura T, Yatsuhashi H, Ide T, Toda N, Nirei K, Ueno Y, Nishigaki Y, Betular J, Gao B, Ishizaki A, Omote M, Mo H, Garrison K, Pang PS, Knox SJ, Symonds WT, McHutchison JG, Izumi N, Omata M. Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial. *Lancet Infect Dis* 2015; **15**: 645-653 [PMID: 25863559 DOI: 10.1016/S1473-3099(15)70099-X]

26 **Lawitz E**, Mangia A, Wyles D, Rodriguez-Torres M, Hassanein T, Gordon SC, Schultz M, Davis MN, Kayali Z, Reddy KR, Jacobson IM, Kowdley KV, Nyberg L, Subramanian GM, Hyland RH, Arterburn S, Jiang D, McNally J, Brainard D, Symonds WT, McHutchison JG, Sheikh AM, Younossi Z, Gane EJ. Sofosbuvir for previously untreated chronic hepatitis C infection. *N Engl J Med* 2013; **368**: 1878-1887 [PMID: 23607594 DOI: 10.1056/NEJMoa1214853]

27 **Lawitz E**, Poordad FF, Pang PS, Hyland RH, Ding X, Mo H, Symonds WT, McHutchison JG, Membreno FE. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial. *Lancet* 2014; **383**: 515-523 [PMID: 24209977 DOI: 10.1016/S0140-6736(13)62121-2]

28 **Afdhal N**, Zeuzem S, Kwo P, Chojkier M, Gitlin N, Puoti M, Romero-Gomez M, Zarski JP, Agarwal K, Buggisch P, Foster GR, Bräu N, Buti M, Jacobson IM, Subramanian GM, Ding X, Mo H, Yang JC, Pang PS, Symonds WT, McHutchison JG, Muir AJ, Mangia A, Marcellin P. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. *N Engl J Med* 2014; **370**: 1889-1898 [PMID: 24725239 DOI: 10.1056/NEJMoa1402454]

29 **Afdhal N**, Reddy KR, Nelson DR, Lawitz E, Gordon SC, Schiff E, Nahass R, Ghalib R, Gitlin N, Herring R, Lalezari J, Younes ZH, Pockros PJ, Di Bisceglie AM, Arora S, Subramanian GM, Zhu Y, Dvory-Sobol H, Yang JC, Pang PS, Symonds WT, McHutchison JG, Muir AJ, Sulkowski M, Kwo P. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. *N Engl J Med* 2014; **370**: 1483-1493 [PMID: 24725238 DOI: 10.1056/NEJMoa1316366]

30 **Kowdley KV**, Gordon SC, Reddy KR, Rossaro L, Bernstein DE, Lawitz E, Shiffman ML, Schiff E, Ghalib R, Ryan M, Rustgi V, Chojkier M, Herring R, Di Bisceglie AM, Pockros PJ, Subramanian GM, An D, Svarovskaia E, Hyland RH, Pang PS, Symonds WT, McHutchison JG, Muir AJ, Pound D, Fried MW. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. *N Engl J Med* 2014; **370**: 1879-1888 [PMID: 24720702 DOI: 10.1056/NEJMoa1402355]

31 **Charlton M**, Everson GT, Flamm SL, Kumar P, Landis C, Brown RS, Fried MW, Terrault NA, O'Leary JG, Vargas HE, Kuo A, Schiff E, Sulkowski MS, Gilroy R, Watt KD, Brown K, Kwo P, Pungpapong S, Korenblat KM, Muir AJ, Teperman L, Fontana RJ, Denning J, Arterburn S, Dvory-Sobol H, Brandt-Sarif T, Pang PS, McHutchison JG, Reddy KR, Afdhal N. Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease. *Gastroenterology* 2015; **149**: 649-659 [PMID: 25985734 DOI: 10.1053/j.gastro.2015.05.010]

32 **Manns M,** Forns X, Samuel D, Denning J, Arterburn S, Brandt-Sarif T, Dvory-Sobol H, Pang PS, McHutchison JG, Gane E, Mutimer D. Ledipasvir/Sofosbuvir With Ribavirin is Safe and Efficacious in Decompensated and Post-Liver Transplantation Patients With HCV Infection: Preliminary Results of the SOLAR-2 Trial. *J Hepatol* 2015; **62**: S187-S188 [DOI: 10.1016/S0168-8278(15)30003-9]

33 **Kwo P**, Gitlin N, Nahass R, Bernstein D, Rojter S, Schiff E, Davis M, Ruane PJ, Younes Z, Kalmeijer R, Peeters M, Lenz O, Fevery B, De La Rosa G, Scott J, Sinha R, Witek J. A Phase 3, Randomised, open-label study to evaluate the efficacy and safety of 12 and 8 weeks of simeprevir (smv) plus sofosbuvir (sof) in treatment-naïve and -experienced patients with chronic hcv genotype 1 infection without cirrhosis: optimist-1. [accessed 2015 Oct 7]. Available from: URL: http://www.viraled.com/modules/info/files/files\_555bae903b796.pdf

34 **Lawitz E**, Matusow G, DeJesus E, Yoshida E, Felizarta F, Ghalib R, Godofsky E, Herring R, Poleynard G, Sheikh A, Tobias H, Kugelmas M, Kalmeijer R, Peeters M, Lenz O, Fevery B, De La Rosa G, Scott J, Sinha R, Witek J. A phase 3, open-label, single-arm study to evaluate the efficacy and safety of 12 weeks of simeprevir (smv) plus sofosbuvir (sof) in treatment-naïve or -experienced patients with chronic hcv genotype 1 infection and cirrhosis: optimist-2. [accessed 2015 Oct 7]. Available from: URL: https://depts.washington.edu/hepstudy/presentations/uploads/157/simepreviroptimist2.pdf#search='CIRRHOSIS%3A+OPTIMIST2

35 **AASLD/IDSA HCV Guidance Panel**. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. *Hepatology* 2015; **62**: 932-954 [PMID: 26111063 DOI: 10.1002/hep.27950]

36 **Jacobson IM**, Gordon SC, Kowdley KV, Yoshida EM, Rodriguez-Torres M, Sulkowski MS, Shiffman ML, Lawitz E, Everson G, Bennett M, Schiff E, Al-Assi MT, Subramanian GM, An D, Lin M, McNally J, Brainard D, Symonds WT, McHutchison JG, Patel K, Feld J, Pianko S, Nelson DR. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. *N Engl J Med* 2013; **368**: 1867-1877 [PMID: 23607593 DOI: 10.1056/NEJMoa1214854]

37 **Zeuzem S**, Dusheiko GM, Salupere R, Mangia A, Flisiak R, Hyland RH, Illeperuma A, Svarovskaia E, Brainard DM, Symonds WT, Subramanian GM, McHutchison JG, Weiland O, Reesink HW, Ferenci P, Hézode C, Esteban R. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. *N Engl J Med* 2014; **370**: 1993-2001 [PMID: 24795201 DOI: 10.1056/NEJMoa1316145]

38 **Omata M**, Nishiguchi S, Ueno Y, Mochizuki H, Izumi N, Ikeda F, Toyoda H, Yokosuka O, Nirei K, Genda T, Umemura T, Takehara T, Sakamoto N, Nishigaki Y, Nakane K, Toda N, Ide T, Yanase M, Hino K, Gao B, Garrison KL, Dvory-Sobol H, Ishizaki A, Omote M, Brainard D, Knox S, Symonds WT, McHutchison JG, Yatsuhashi H, Mizokami M. Sofosbuvir plus ribavirin in Japanese patients with chronic genotype 2 HCV infection: an open-label, phase 3 trial. *J Viral Hepat* 2014; **21**: 762-768 [PMID: 25196837 DOI: 10.1111/jvh.12312]

39 **Nelson DR**, Cooper JN, Lalezari JP, Lawitz E, Pockros PJ, Gitlin N, Freilich BF, Younes ZH, Harlan W, Ghalib R, Oguchi G, Thuluvath PJ, Ortiz-Lasanta G, Rabinovitz M, Bernstein D, Bennett M, Hawkins T, Ravendhran N, Sheikh AM, Varunok P, Kowdley KV, Hennicken D, McPhee F, Rana K, Hughes EA. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. *Hepatology* 2015; **61**: 1127-1135 [PMID: 25614962 DOI: 10.1002/hep.27726]

40 **Abergel A**, Loustaud-Ratti V, Metivier S, Jiang D, Kersey K, Knox SJ, Pang PS, Samuel D, Asselah T. Ledipasvir/sofosbuvir treatment results in high SVR rates in patients with chronic genotype 4 and 5 HCV infection. *J Hepatol* 2015; **62**: S219-S220 [DOI: 10.1016/S0168-8278(15)30070-2]

41 **Sulkowski MS**, Naggie S, Lalezari J, Fessel WJ, Mounzer K, Shuhart M, Luetkemeyer AF, Asmuth D, Gaggar A, Ni L, Svarovskaia E, Brainard DM, Symonds WT, Subramanian GM, McHutchison JG, Rodriguez-Torres M, Dieterich D. Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection. *JAMA* 2014; **312**: 353-361 [PMID: 25038354 DOI: 10.1001/jama.2014.7734]

42 **Molina JM**, Orkin C, Iser DM, Zamora FX, Nelson M, Stephan C, Massetto B,Gaggar A, Ni L, Svarovskaia E, Brainard D, Subramanian GM, McHutchison JG, Puoti M, Rockstroh JK; PHOTON-2 study team. Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, non-randomised, phase 3 study. *Lancet* 2015; **385**: 1098-1106 [PMID: 25659285 DOI: 10.1016/S0140-6736(14)62483-1]

43 **Wyles DL**, Ruane PJ, Sulkowski MS, Dieterich D, Luetkemeyer A, Morgan TR, Sherman KE, Dretler R, Fishbein D, Gathe JC, Henn S, Hinestrosa F, Huynh C, McDonald C, Mills A, Overton ET, Ramgopal M, Rashbaum B, Ray G, Scarsella A, Yozviak J, McPhee F, Liu Z, Hughes E, Yin PD, Noviello S, Ackerman P. Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1. *N Engl J Med* 2015; **373**: 714-725 [PMID: 26196502 DOI: 10.1056/NEJMoa1503153]

44 **Naggie S**, Cooper C, Saag M, Workowski K, Ruane P, Towner WJ, Marks K, Luetkemeyer A, Baden RP, Sax PE, Gane E, Santana-Bagur J, Stamm LM, Yang JC, German P, Dvory-Sobol H, Ni L, Pang PS, McHutchison JG, Stedman CA, Morales-Ramirez JO, Bräu N, Jayaweera D, Colson AE, Tebas P, Wong DK, Dieterich D, Sulkowski M. Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1. *N Engl J Med* 2015; **373**: 705-713 [PMID: 26196665 DOI: 10.1056/NEJMoa1501315]

**P-Reviewer:** da Silva NMO, Felmlee DJ, Parvez MK **S-Editor:** Qi Y **L-Editor: E-Editor:**

**Table 1 Summary of Phase 3 study for hepatitis C virus genotype 1-infected patients**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Study name | Population | Treatment | Duration (wk) | *n* | LC (%) | SVR12 (%) |
|  |  |  |  |  |  | All | non-LC | LC |
| NEUTRINO | Naïve | SOF/PEG-IFN/RBV | 12 | 291 | - | 89 | - | 81 |
| ION-1 | Naïve | SOF/LDV | 12 | 210 | 16 | 99 | 100 | 97 |
|  |  | SOF/LDV/RBV | 12 | 216 | 15 | 97 | 97 | 100 |
|  |  | SOF/LDV | 24 | 214 | 15 | 98 | 99 | 97 |
|  |  | SOF/LDV/RBV | 24 | 214 | 17 | 99 | 99 | 100 |
| ION-3 | Naïve | SOF/LDV | 8 | 214 | 0 | 94 | 94 | - |
|  |  | SOF/LDV/RBV | 8 | 216 | 0 | 93 | 93 | - |
|  |  | SOF/LDV | 12 | 216 | 0 | 95 | 95 | - |
| Japanese study | Naïve | SOF/LDV | 12 | 83 | 16 | 100 | 100 | 100 |
|  |  | SOF/LDV/RBV | 12 | 83 | 14 | 96 | 97 | 92 |
|  |  |  |  |  |  |  |  |  |
| ION-2 | Experienced | SOF/LDV | 12 | 20 | 94 | 95 | 86 | 20 |
|  |  | SOF/LDV/RBV | 12 | 20 | 96 | 100 | 82 | 20 |
|  |  | SOF/LDV | 24 | 20 | 99 | 99 | 100 | 20 |
|  |  | SOF/LDV/RBV | 24 | 20 | 99 | 99 | 100 | 20 |
| Japanese study | Experienced | SOF/LDV | 12 | 32 | 100 | 100 | 100 | 32 |
|  |  | SOF/LDV/RBV | 12 | 25 | 100 | 100 | 100 | 25 |

LC: Liver cirrhosis; SVR12: Sustained virologic response at 12 wk; Naïve: Treatment-naïve; Experienced: Treatment-experienced; SOF: Sofosbuvir; LDV: Ledipasvir; PEG-IFN: Peginterferon; RBV: Ribavirin.

**Table 2 Summary of Phase 3 study for hepatitis C virus genotype 2-infected patients**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Study name | Population | Treatment | Duration (wk) | *n* | LC (%) | SVR12 (%) |
|  |  |  |  |  |  | All | non-LC | LC |
| FISSION | Naïve | SOF/RBV | 12 | 70 | - | 97 | - | - |
| POSITRON | IFN-ineligible/intolerant | SOF/RBV | 12 | 109 | 15 | 93 | 92 | 94 |
| VALENCE | Naïve | SOF/RBV | 12 | 32 | - | 97 | 97 | 100 |
| Japanese study | Naïve | SOF/RBV | 12 | 90 | 9 | 98 | 97 | 100 |
|  |  |  |  |  |  |  |  |  |
| FUSION | Experienced | SOF/RBV | 12 | 36 | 28 | 86 | 96 | 60 |
|  |  |  | 16 | 32 | - | 94 | 100 | 78 |
| VALENCE | Experienced | SOF/RBV | 12 | 41 | - | 90 | 91 | 88 |
| Japanese study | Experienced | SOF/RBV | 12 | 63 | 14 | 95 | 96 | 89 |

LC: Liver cirrhosis; SVR12: Sustained virologic response at 12 wk; Naïve: Treatment-naïve; Experienced: Treatment-experienced; SOF: Sofosbuvir; LDV: Ledipasvir; PEG-IFN: Peginterferon; RBV: Ribavirin.

**Table 3 Summary of phase 3 study for hepatitis C virus genotype 3-infected patients**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Study name | Population | Treatment | Duration (wk) | *n* | LC (%) | SVR12 (%) |
|  |  |  |  |  |  | All | non-LC | LC |
| FISSION | Naïve | SOF/RBV | 12 | 183 | - | 56 | - | - |
| POSITRON | IFN-ineligible/intolerant | SOF/RBV | 12 | 98 | 15 | 61 | 68 | 21 |
| VALENCE | Naïve | SOF/RBV | 24 | 105 | 12 | 93 | 95 | 92 |
|  |  |  |  |  |  |  |  |  |
| FUSION | Experienced | SOF/RBV | 12 | 64 | 39 | 30 | 37 | 19 |
|  |  |  | 16 | 63 | - | 62 | 63 | 61 |
| VALENCE | Experienced | SOF/RBV | 24 | 145 | 32 | 79 | 87 | 62 |

LC: Liver cirrhosis; SVR12: Sustained virologic response at 12 wk; Naïve: Treatment-naïve; Experienced: Treatment-experienced; SOF: Sofosbuvir; LDV: Ledipasvir; PEG-IFN: Peginterferon; RBV: Ribavirin.

**Table 4 Summary of Phase 3 study for hepatitis C virus-HIV Co-infected patients**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Genotype | Study name | Population | Treatment | Duration (wk) | *n* | LC (%) | SVR12 (%) |
| 1 | PHOTON-1 | Naïve | SOF/RBV | 12 | 114 | 4.4 | 76 |
|  | PHOTON-2 | Naïve | SOF/RBV | 24 | 112 | 15 | 85 |
|  |  |  |  |  |  |  |  |
| 2 | PHOTON-1 | Naïve | SOF/RBV | 12 | 26 | - | 88 |
|  |  | Experienced | SOF/RBV | 24 | 24 | - | 92 |
|  | PHOTON-2 | Naïve | SOF/RBV | 12 | 19 | 5 | 89 |
|  |  | Experienced | SOF/RBV | 24 | 6 | 33 | 83 |
|  |  |  |  |  |  |  |  |
| 3 | PHOTON-1 | Naïve | SOF/RBV | 12 | 42 | - | 67 |
|  |  | Experienced | SOF/RBV | 24 | 17 | - | 94 |
|  | PHOTON-2 | Naïve | SOF/RBV | 24 | 57 | 5 | 91 |
|  |  | Experienced | SOF/RBV | 24 | 49 | 47 | 86 |
|  |  |  |  |  |  |  |  |
| 4 | PHOTON-2 | Naïve | SOF/RBV | 24 | 31 | 26 | 84 |

LC: Liver cirrhosis; SVR12: Sustained virologic response at 12 wk; Naïve: Treatment-naïve; Experienced: Treatment-experienced; SOF: Sofosbuvir; LDV: Ledipasvir; PEG-IFN: Peginterferon; RBV: Ribavirin.